Asier Benito-Vicente

List of Publications by Year
in descending order

27	649	623188 14	642321 23
papers	citations	h-index	g-index

27	27	27	833
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Tripleâ€Cell 2D Atherosclerosis Model. Small, 2022, 18, e2105915.	5.2	13
2	Familial hypercholesterolemia. , 2022, , 501-524.		0
3	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 934-943.	1.1	5
4	Molecular mechanisms of lipotoxicity-induced pancreatic Î²-cell dysfunction. International Review of Cell and Molecular Biology, 2021, 359, 357-402.	1.6	28
5	(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?. Biomaterials Science, 2021, 9, 3185-3208.	2.6	5
6	MLb-LDLr. JACC Basic To Translational Science, 2021, 6, 815-827.	1.9	10
7	A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants. International Journal of Molecular Sciences, 2021, 22, 13602.	1.8	10
8	Cholesterol Efflux Efficiency of Reconstituted HDL Is Affected by Nanoparticle Lipid Composition. Biomedicines, 2020, 8, 373.	1.4	11
9	miR-27b Modulates Insulin Signaling in Hepatocytes by Regulating Insulin Receptor Expression. International Journal of Molecular Sciences, 2020, 21, 8675.	1.8	14
10	Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR. Scientific Reports, 2020, 10, 1727.	1.6	23
11	The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. Atherosclerosis, 2019, 289, 162-172.	0.4	21
12	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2248-2260.	1.1	60
13	Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions. Journal of Biological Chemistry, 2018, 293, 7408-7422.	1.6	57
14	Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. International Journal of Molecular Sciences, 2018, 19, 3426.	1.8	78
15	Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia. Atherosclerosis, 2018, 277, 448-456.	0.4	23
16	Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants. International Journal of Molecular Sciences, 2018, 19, 1676.	1.8	37
17	Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene. Atherosclerosis, 2017, 263, 163-170.	0.4	13
18	Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia. Scientific Reports, 2017, 7, 15282.	1.6	37

#	Article	IF	Citations
19	Structural changes induced by acidic pH in human apolipoprotein B-100. Scientific Reports, 2016, 6, 36324.	1.6	14
20	The use of targeted exome sequencing in genetic diagnosis of young patients with severe hypercholesterolemia. Scientific Reports, 2016, 6, 36823.	1.6	13
21	The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2113-2121.	1.8	71
22	Characterization of the First PCSK9 Gain of Function Homozygote. Journal of the American College of Cardiology, 2015, 66, 2152-2154.	1.2	30
23	The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia. Genetics in Medicine, 2015, 17, 980-988.	1.1	35
24	Functional Characterization and Classification of Frequent Low-Density Lipoprotein Receptor Variants. Human Mutation, 2015, 36, 129-141.	1.1	41
25	MLb-LDLr: LDLaren hartzaile aldaeren eragina aurresateko ikasketa automatikoko eredua. , 0, , .		0
26	ACT toxina eta mintzeko kolesterolaren arteko elkarrekintzaren azterketa. , 0, , .		0
27	Nanopartikulen lipido konposizioak rHDLen kolesterol kanpora-fluxuaren efizientzian eragina du. , 0, , .		0